Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of vepoloxamer (MST-188) in patients with acute decompensated heart failure

Trial Profile

Phase II trial of vepoloxamer (MST-188) in patients with acute decompensated heart failure

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Acute heart failure; Decompensated heart failure
  • Focus Biomarker; Therapeutic Use
  • Sponsors Mast Therapeutics; Savara Pharmaceuticals
  • Most Recent Events

    • 11 Feb 2015 According to a Mast Therapeutics media release, is planning to initiate this Phase 2 study in the second quarter of 2015
    • 09 Dec 2014 The US FDA has granted permission for the study to proceed, according to a Mast Therapeutics media release.
    • 24 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top